Parvovirus B19 Passive Transmission by Transfusion of Intercept® Blood System-Treated Platelet Concentrate

Transfusion Medicine and Hemotherapy

Volumn 43, Issue 3, 2016, Pages 198-202

  Gowland, Peter ^a   Fontana, Stefano ^a   Stolz, Martin ^a   Andina, Nicola ^b   Niederhauser, Christoph ^a  

^a Blood Transfusion Service SRC Berne   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Parvovirus B19; Pathogen inactivation; Pathogen reduction; Platelet transfusion; Transfusion associated infections

Indexed keywords

AMOTOSALEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; NONOXINOL 9; THROMBOCYTE CONCENTRATE;

AGED; ARTICLE; BLOOD SAMPLING; BLOOD TRANSFUSION; CASE REPORT; DNA SEQUENCE; DONOR SELECTION; ERYTHEMA INFECTIOSUM; FEMALE; HUMAN; HUMAN PARVOVIRUS B19; IMMUNE STATUS; IMMUNOBLOTTING; MALE; PATHOGEN REDUCTION SYSTEM; PHYLOGENY; POLYMERASE CHAIN REACTION; SEROLOGY; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 84966318891     PISSN: 16603796     EISSN: 16603818     Source Type: Journal    
DOI: 10.1159/000445195     Document Type: Article

References (26)

1. Young NS, Brown KE: Parvovirus B19. N Engl J Med 2004; 350: 586-597.
2. Mitteilungen des Arbeitskreises Blut des Bundesministeriums für Gesundheit. Bundesgesundheitsblatt 2010; 53: 944-956
3. Blümel J, Schmidt I, Effenberger W, Seitz H, Willkommen H, Brackmann HH, et al: Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion 2002; 42: 1473-1481.
4. Satake M, Hoshi Y, Taira R, Momose SY, Hino S, Tadokoro K: Symptomatic parvovirus B19 infection caused by blood component transfusion. Transfusion 2011; 51: 1887-1895.
5. Kleinman SH, Glynn SA, Lee TH, Tobler LH, Schlumpf KS, Todd DS, et al: A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion. Blood 2009; 114: 3677-3683.
6. Hourfar MK, Mayr-Wohlfart U, Themann A, Sireis W, Seifried E, Schrezenmeier H, et al: Recipients potentially infected with parvovirus B19 by red blood cell products. Transfusion 2011; 51: 129-136.
7. Corcoran A, Doyle S: Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. J Med Microbiol 2004; 53: 459-475.
8. Parsyan A, Candotti D: Human erythrovirus B19 and blood transfusion-an update. Transfus Med 2007; 4: 263-278.
9. Yu MY, Alter HJ, Virata-Theimer ML, Geng Y, Ma L, Schechterly CA, et al: Parvovirus B19 infection transmitted by transfusion of red blood cells confirmed by molecular analysis of linked donor and recipient samples. Transfusion 2010; 50: 1712-1721.
10. Juhl D, Özdemir M, Dreier J, Görg S, Hennig H: Lookback study on recipients of Parvovirus B19 (B19V) DNA-positive blood components. Vox Sang 2015; 109: 305-11
11. Brown KE, Simmonds P: Parvoviruses and blood transfusion. Transfusion 2007; 47: 1745-1750.
12. Wu CG, Mason B, Jong J, Erdmann D, McKernan L, Oakley M, et al: Parvovirus B19 transmission by a high-purity factor VIII concentrate. Transfusion 2005; 45: 1003-1010.
13. Brown KE, Young NS, Alving BM, Barbosa LH: Parvovirus B19: implications for transfusion medicine. Summary of a workshop. Transfusion 2001; 41: 130-135.
14. Prowse CV: Component pathogen inactivation: a critical review. Vox Sang 2013; 104: 183-199.
15. Irsch J, Lin L: pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT Blood SystemTM. Transfus Med Hemother 2011; 38: 19-31.
16. Blutspende SRK Schweiz: Vorschriften/Empfehlungen/mitgeltende Dokumente. Kapitel 18 B: Spezifikationen: Thrombozytenkonzentrate. https://sbsc-bsd. ch/dokuman/DokumenteBSD/Allgemeines/tabid/107/Default.aspx (last accessed April 6, 2016)
17. Sawyer L, Hanson D, Castro G, Luckett W, Dubensky TW Jr, Stassinopoulos A: Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination. Transfusion 2007; 47: 1062-70.
18. Lin L, Hanson CV, Alter HJ, Jauvin V, Bernard KA, Murthy KK, et al: Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005; 45: 580-590.
19. Candotti D, Etiz N, Parsyan A, Allain JP: Identification and characterization of persistent human erythrovirus infection in blood donor samples. J Virol 2004; 78: 12169-12178.
20. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, et al: Clustal W and Clustal X version 2.0. Bioinformatics 2007; 23: 2947-2948.
21. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S: MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol 2013; 30: 2725-2729.
22. Hauser L, Roque-Afonso AM, Beylouné A, Simmonet M, Fischer BD, des Roziers NB, et al: Hepatitis E transmission by transfusion of Intercept blood systemtreated plasma. Blood 2014 30; 123: 796-797.
23. Prowse C, Ludlam CA, Yap PL: Human parvovirus B19 and blood products. Vox Sang 1997; 72: 1-10.
24. Kooistra K, Mesman HJ, de Waal M, Koppelman MH, Zaaijer HL: Epidemiology of high-level parvovirus B19 viraemia among Dutch blood donors, 2003-2009. Vox Sang 2011; 100: 261-266.
25. Schmidt M, Themann A, Drexler C, Bayer M, Lanzer G, Menichetti E, et al: Blood donor screening for parvovirus B19 in Germany and Austria. Transfusion 2007; 47: 1775-1782 26 Röhrer C, Gärtner B, Sauerbrei A, Böhm S, Hottenträger B, Raab U, et al: Seroprevalence of parvovirus B19 in the German population. Epidemiol Infect 2008; 136: 1564-1575.
26. Doyle S, Corcoran A: The immune response to parvovirus B19 exposure in previously seronegative and seropositive individuals. J Infect Dis 2006; 194: 154-158